The Centers for Medicare and Medicaid Services (CMS) has finished setting the rules and numbers health insurers need to design the individual commercial major medical insurance policies for 2020.

Large drug makers and the industry’s primary trade group neared previous spending records on lobbying in the first three months of the year as President Donald Trump and Congress increased pressure to rein in the cost of medicine.

CMS is taking aim at increasing the use of generic drugs in ACA plans in a new rule filed Thursday evening.

The White House and top lawmakers from both parties think a bill to lower drug prices has a better chance of becoming law before the 2020 election than any other controversial legislation.

The CMS finalized a rule on Thursday that would allow health insurers to implement copay accumulator programs to prevent drug manufacturer coupons from applying to a patient's annual limit on out-of-pocket costs in situations where a generic drug is available.

The Congressional Budget Office has announced that it will be using a new model for budget projections that will account for new consumer and employer preferences when it estimates how proposed legislation will affect insurance coverage and premiums.